

Baskar, P.
10/762058

10/762058

FILE 'CAPLUS' ENTERED AT 16:16:26 ON 21 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Jul 2006 VOL 145 ISS 5
FILE LAST UPDATED: 20 Jul 2006 (20060720/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

- key terms

L1 1 SEA FILE=CAPLUS ABB=ON PLU=ON CT875 OR CT 875

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 18 Oct 2002

ACCESSION NUMBER: 2002:793930 CAPLUS
DOCUMENT NUMBER: 137:307015
TITLE: Method for identification of proteins from intracellular bacteria
INVENTOR(S): Shaw, Allan Christian; Vandahl, Brian Berg
PATENT ASSIGNEE(S): Den.
SOURCE: PCT Int. Appl., 179 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002082091	A2	20021017	WO 2002-DK234	20020409
WO 2002082091	A3	20040304		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2443813	AA	20021017	CA 2002-2443813	20020409
US 2003199438	A1	20031023	US 2002-119536	20020409
BR 2002008786	A	20040309	BR 2002-8786	20020409
EP 1412757	A2	20040428	EP 2002-759766	20020409
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,			

Searcher : Shears 571-272-2528

PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1531653	A	20040922	CN 2002-809114	20020409
JP 2004534526	T2	20041118	JP 2002-579810	20020409
US 2005239160	A1	20051027	US 2004-996306	20041123
PRIORITY APPLN. INFO.:			DK 2001-581	A 20010409
			US 2001-282513P	P 20010409
			US 2002-119536	B1 20020409
			WO 2002-DK234	W 20020409

AB The present invention relates to a novel combination of methods that enables identification of proteins secreted from intracellular bacteria regardless of the secretion pathway. The invention further provides proteins that are identified by these methods. Secreted proteins are known to be suitable candidates for inclusion in immunogenic comps. and/or diagnostic purposes. The invention also provides peptide epitopes (T-cell epitopes) from the identified secreted proteins, as well as nucleic acid compds. that encode the proteins. The invention further comprises various applications of the proteins or fragments thereof, such as pharmaceutical and diagnostic applications.

FILE 'MEDLINE' ENTERED AT 16:16:26 ON 21 JUL 2006

FILE 'BIOSIS' ENTERED AT 16:16:26 ON 21 JUL 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 16:16:26 ON 21 JUL 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 16:16:26 ON 21 JUL 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'CONFSCI' ENTERED AT 16:16:26 ON 21 JUL 2006
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'SCISEARCH' ENTERED AT 16:16:26 ON 21 JUL 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'JICST-EPLUS' ENTERED AT 16:16:26 ON 21 JUL 2006
COPYRIGHT (C) 2006 Japan Science and Technology Agency (JST)

FILE 'JAPIO' ENTERED AT 16:16:26 ON 21 JUL 2006
COPYRIGHT (C) 2006 Japanese Patent Office (JPO)- JAPIO

L2 0 L1

FILE 'USPATFULL' ENTERED AT 16:16:46 ON 21 JUL 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 20 Jul 2006 (20060720/PD)
FILE LAST UPDATED: 20 Jul 2006 (20060720/ED)
HIGHEST GRANTED PATENT NUMBER: US7080410
HIGHEST APPLICATION PUBLICATION NUMBER: US2006162035
CA INDEXING IS CURRENT THROUGH 20 Jul 2006 (20060720/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 20 Jul 2006 (20060720/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2006

L3 14 S L1
 L4 13 S L3 (L) CHLAMYD?

L4 ANSWER 1 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2006:40224 USPATFULL
 TITLE: Immunogenic compositions for Chlamydia trachomatis
 INVENTOR(S): Grandi, Guido, Milano, ITALY
 Ratti, Guilio, Siena, ITALY
 Bonci, Alessandra, Siena, ITALY
 Finco, Oretta, Castelnuovo Berardenga, ITALY
 PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, UNITED STATES
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006034871	A1	20060216
APPLICATION INFO.:	US 2004-18868	A1	20041222 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2004-US20491, filed on 25 Jun 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2003-15020	20030626
	GB 2004-2236	20040202
	US 2003-497649P	20030825 (60)
	US 2004-576375P	20040601 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097, US	
NUMBER OF CLAIMS:	45	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	9932	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to immunogenic compositions comprising combinations of Chlamydia trachomatis antigens and their use in vaccines. The composition may comprise at least two components, one component of which comprises Chlamydia trachomatis antigens for eliciting a Chlamydia trachomatis specific TH1 immune response and another component of which comprises antigens for eliciting a Chlamydia trachomatis specific TH2 immune response. The invention further relates to an immunogenic composition comprising a Chlamydia trachomatis Type III secretion system (TTSS) regulatory protein and a Chlamydia trachomatis Type III secretion system (TTSS) secreted protein or a fragment thereof. The invention further relates to the use of combinations of adjuvants for use with antigens associated with a sexually transmissible disease, such as Chlamydia trachomatis antigens. Preferred adjuvant combinations include mineral salts, such as aluminium salts and oligonucleotides comprising a CpG motif. The invention further provides a combination of Chlamydia trachomatis antigens comprising a Chlamydia trachomatis antigen that is conserved over at least two serovars.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

INCL INCLM: 424/263.100
 INCLS: 435/252.300
 NCL NCLM: 424/263.100
 NCLS: 435/252.300

L4 ANSWER 2 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2005:274604 USPATFULL
TITLE: Method for identification of proteins from
intracellular bacteria
INVENTOR(S): Shaw, Allan Christian, Aarhus C, DENMARK
Vandahl, Brian Berg, Aarhus N, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005239160	A1	20051027
APPLICATION INFO.:	US 2004-996306	A1	20041123 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-119536, filed on 9 Apr 2002, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2001-581	20010409
	US 2001-282513P	20010409 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DARBY & DARBY P.C., P. O. BOX 5257, NEW YORK, NY, 10150-5257, US	
NUMBER OF CLAIMS:	89	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	7621	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel combination of methods that enables identification of proteins secreted from intracellular bacteria regardless of the secretion pathway. The invention further provides proteins that are identified by these methods. Secreted proteins are known to be suitable candidates for inclusion in immunogenic compositions and/or diagnostic purposes. The invention also provides peptide epitopes (T-cell epitopes) from the identified secreted proteins, as well as nucleic acid compounds that encode the proteins. The invention further comprises various applications of the proteins or fragments thereof, such as pharmaceutical and diagnostic applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

INCL INCLM: 435/034.000
NCL NCLM: 435/034.000

L4 ANSWER 3 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2005:267625 USPATFULL
TITLE: Compounds and methods for treatment and diagnosis
of chlamydial infection
INVENTOR(S): Bhatia, Ajay, Seattle, WA, UNITED STATES
Guderian, Jeff, Lynnwood, WA, UNITED STATES
Skeiky, Yasir A W., Silver Spring, MD, UNITED
STATES
Maisonneuve, Jean-Francois L., Federal Way, WA,
UNITED STATES
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005232941	A1	20051020

APPLICATION INFO.: US 2005-109468 A1 20050419 (11)
 RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-197220, filed on
 15 Jul 2002, GRANTED, Pat. No. US 6919187
 Continuation-in-part of Ser. No. US 2001-7693,
 filed on 5 Dec 2001, PENDING Continuation-in-part
 of Ser. No. US 2001-12256, filed on 6 Nov 2001,
 ABANDONED Continuation-in-part of Ser. No. US
 2001-841260, filed on 23 Apr 2001, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-219752P	20000720 (60)
	US 2000-198853P	20000421 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092, US	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4537	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biological samples.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

INCL INCLM: 424/190.100
 INCLS: 435/006.000; 435/007.320; 435/069.300; 435/252.300;
 435/372.000; 530/350.000; 536/023.700
 NCL NCLM: 424/190.100
 NCLS: 435/006.000; 435/007.320; 435/069.300; 435/252.300;
 435/372.000; 530/350.000; 536/023.700

L4 ANSWER 4 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2005:98584 USPATFULL
 TITLE: COMPOUNDS AND METHODS FOR TREATMENT AND DIAGNOSIS
 OF CHLAMYDIAL INFECTION
 INVENTOR(S): Bhatia, Ajay, Seattle, WA, UNITED STATES
 Guderian, Jeff, Lynnwood, WA, UNITED STATES
 Skeiky, Yasir A. W., Bellevue, WA, UNITED STATES
 Maisonneuve, Jean-Francois L., Seattle, WA, UNITED STATES
 PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005084499	A1	20050421
	US 6919187	B2	20050719
APPLICATION INFO.:	US 2002-197220	A1	20020715 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-7693, filed on 5 Dec 2001, PENDING Continuation-in-part of Ser. No. US 2001-12256, filed on 6 Nov 2001,		

ABANDONED Continuation-in-part of Ser. No. US
2001-841260, filed on 23 Apr 2001, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-219752P	20000720 (60)
	US 2000-198853P	20000421 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092, US	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1-2	
LINE COUNT:	12039	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biological samples.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

INCL INCLM: 424/190.100

INCLS: 530/350.000

NCL NCLM: 435/069.100; 424/190.100

NCLS: 424/190.100; 424/200.100; 424/263.100; 514/044.000;
536/023.100; 536/023.700; 530/350.000

L4 ANSWER 5 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2004:298674 USPATFULL

TITLE: Compounds and methods for treatment and diagnosis
of chlamydial infection

INVENTOR(S): Bhatia, Ajay, Seattle, WA, UNITED STATES
Skeiky, Yasir A.W., Bellevue, WA, UNITED STATES
Probst, Peter, Seattle, WA, UNITED STATES

PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES,
98104 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004234536	A1	20041125
APPLICATION INFO.:	US 2004-872155	A1	20040618 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-841132, filed on 23 Apr 2001, ABANDONED Continuation-in-part of Ser. No. US 2000-620412, filed on 20 Jul 2000, GRANTED, Pat. No. US 6448234 Continuation-in-part of Ser. No. US 2000-598419, filed on 20 Jun 2000, GRANTED, Pat. No. US 6565856 Continuation-in-part of Ser. No. US 2000-556877, filed on 19 Apr 2000, GRANTED, Pat. No. US 6432916 Continuation-in-part of Ser. No. US 1999-454684, filed on 3 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-426571, filed on 22 Oct 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-410568, filed on 1 Oct 1999, GRANTED, Pat. No. US 6555115		

Continuation-in-part of Ser. No. US 1999-288594,
 filed on 8 Apr 1999, GRANTED, Pat. No. US 6447779
 Continuation-in-part of Ser. No. US 1998-208277,
 filed on 8 Dec 1998, GRANTED, Pat. No. US 6166177

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701
 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

NUMBER OF CLAIMS: 10
 EXEMPLARY CLAIM: CLM-01-18
 NUMBER OF DRAWINGS: 11 Drawing Page(s)
 LINE COUNT: 5306
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds and methods for the diagnosis and treatment of Chlamydial
 infection are disclosed. The compounds provided include polypeptides
 that contain at least one antigenic portion of a Chlamydia antigen
 and DNA sequences encoding such polypeptides. Pharmaceutical
 compositions and vaccines comprising such polypeptides or DNA
 sequences are also provided, together with antibodies directed
 against such polypeptides. Diagnostic kits containing such
 polypeptides or DNA sequences and a suitable detection reagent may
 be used for the detection of Chlamydial infection in patients and in
 biological samples.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

INCL INCLM: 424/184.100
 NCL NCLM: 424/184.100

L4 ANSWER 6 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2004:177843 USPATFULL
 TITLE: Compounds and methods for treatment and diagnosis
 of chlamydial infection
 INVENTOR(S): Bhatia, Ajay, Seattle, WA, UNITED STATES
 Probst, Peter, Seattle, WA, UNITED STATES
 Stromberg, Erika Jean, Seattle, WA, UNITED STATES
 PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES,
 98104 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004137007	A1	20040715
APPLICATION INFO.:	US 2004-762058	A1	20040115 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-841260, filed on 23 Apr 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-198853P	20000421 (60)
	US 2000-219752P	20000720 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701
 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

NUMBER OF CLAIMS: 18
 EXEMPLARY CLAIM: 1
 LINE COUNT: 4173
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds and methods for the diagnosis and treatment of Chlamydial
 infection are disclosed. The compounds provided include polypeptides
 that contain at least one antigenic portion of a Chlamydia antigen

and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biological samples.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

INCL INCLM: 424/185.100
INCLS: 514/042.000; 514/044.000; 514/054.000
NCL NCLM: 424/185.100
NCLS: 514/042.000; 514/044.000; 514/054.000

L4 ANSWER 7 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2003:283094 USPATFULL
TITLE: Method for identification of proteins from intracellular bacteria
INVENTOR(S): Shaw, Allan Christian, Aarhus C, DENMARK
Vandahl, Brian Berg, Aarhus N, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199438	A1	20031023
APPLICATION INFO.:	US 2002-119536	A1	20020409 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2001-581	20010409
	US 2001-282513P	20010409 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DARBY & DARBY P.C., P. O. BOX 5257, NEW YORK, NY, 10150-5257	
NUMBER OF CLAIMS:	72	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	3593	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel combination of methods that enables identification of proteins secreted from intracellular bacteria regardless of the secretion pathway. The invention further provides proteins that are identified by these methods. Secreted proteins are known to be suitable candidates for inclusion in immunogenic compositions and/or diagnostic purposes. The invention also provides peptide epitopes (T-cell epitopes) from the identified secreted proteins, as well as nucleic acid compounds that encode the proteins. The invention further comprises various applications of the proteins or fragments thereof, such as pharmaceutical and diagnostic applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

INCL INCLM: 514/012.000
INCLS: 435/034.000
NCL NCLM: 514/012.000
NCLS: 435/034.000

L4 ANSWER 8 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2003:250914 USPATFULL
TITLE: Compounds and methods for treatment and diagnosis

INVENTOR(S): of chlamydial infection
 Bhatia, Ajay, Seattle, WA, UNITED STATES
 Probst, Peter, Seattle, WA, UNITED STATES
 Stromberg, Erika Jean, Seattle, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175700	A1	20030918
APPLICATION INFO.:	US 2001-841260	A1	20010423 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-198853P	20000421 (60)
	US 2000-219752P	20000720 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	9573	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biological samples.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

INCL INCLM: 435/006.000
 INCLS: 435/007.360; 435/069.300; 435/252.300; 435/320.100;
 435/183.000; 536/023.700; 530/350.000; 424/190.100
 NCL NCLM: 435/006.000
 NCLS: 424/190.100; 435/007.360; 435/069.300; 435/183.000;
 435/252.300; 435/320.100; 530/350.000; 536/023.700

L4 ANSWER 9 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2003:136801 USPATFULL
 TITLE: Compounds and methods for treatment and diagnosis
 of chlamydial infection
 INVENTOR(S): Skeiky, Yasir A. W., Bellevue, WA, United States
 Scholler, John, Seattle, WA, United States
 PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, United States
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6565856	B1	20030520
APPLICATION INFO.:	US 2000-598419		20000620 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-556877, filed on 20 Jun 2000, now patented, Pat. No. US 6432916, issued on 13 Aug 2002 Continuation-in-part of Ser. No. US 1999-454684, filed on 3 Dec 1999 Continuation of Ser. No. US 1999-426571, filed on 22 Oct 1999 Continuation-in-part of Ser. No. US		

10/762058

1999-410568, filed on 1 Oct 1999
Continuation-in-part of Ser. No. US 1999-288594,
filed on 8 Apr 1999, now patented, Pat. No. US
6447779, issued on 10 Sep 2002 Continuation-in-part
of Ser. No. US 1998-208277, filed on 8 Dec 1998,
now patented, Pat. No. US 6166177, issued on 26 Dec
2000 .

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Smith, Lynette R. F.
ASSISTANT EXAMINER: Ford, Vanessa L.
LEGAL REPRESENTATIVE: Seed Intellectual Property Law Group PLLC
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 11549

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds and methods for the diagnosis and treatment of Chlamydial
infection are disclosed. The compounds provided include polypeptides
that contain at least one antigenic portion of a Chlamydia antigen
and DNA sequences encoding such polypeptides. Pharmaceutical
compositions and vaccines comprising such polypeptides or DNA
sequences are also provided, together with antibodies directed
against such polypeptides. Diagnostic kits containing such
polypeptides or DNA sequences and a suitable detection reagent may
be used for the detection of Chlamydial infection in patients and in
biological samples.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

INCL INCLM: 424/263.100
INCLS: 424/282.100; 435/007.320; 435/007.360; 435/243.000;
435/252.100; 530/300.000; 530/387.300
NCL NCLM: 424/263.100
NCLS: 424/282.100; 435/007.320; 435/007.360; 435/243.000;
435/252.100; 530/300.000; 530/387.300

L4 ANSWER 10 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2002:265900 USPATFULL
TITLE: Compounds and methods for treatment and diagnosis
of chlamydial infection
INVENTOR(S): Bhatia, Ajay, Seattle, WA, UNITED STATES
Probst, Peter, Seattle, WA, UNITED STATES
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES,
98104 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002146776	A1	20021010
APPLICATION INFO.:	US 2001-7693	A1	20011205 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-841260, filed on 23 Apr 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-219752P	20000720 (60)
	US 2000-198853P	20000421 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701
FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

Searcher : Shears 571-272-2528

NUMBER OF CLAIMS: 17
 EXEMPLARY CLAIM: 1
 LINE COUNT: 4342

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biological samples.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

INCL INCLM: 435/069.300
 INCLS: 435/252.300; 435/320.100; 435/183.000; 536/023.700
 NCL NCLM: 435/069.300
 NCLS: 435/183.000; 435/252.300; 435/320.100; 536/023.700

L4 ANSWER 11 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2002:230962 USPATFULL
 TITLE: Compounds and methods for treatment and diagnosis of chlamydial infection
 INVENTOR(S): Fling, Steven P., Bainbridge Island, WA, United States
 PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6448234	B1	20020910
APPLICATION INFO.:	US 2000-620412		20000720 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-598419, filed on 20 Jun 2000 Continuation-in-part of Ser. No. US 2000-556877, filed on 19 Apr 2000 Continuation-in-part of Ser. No. US 1999-454684, filed on 3 Dec 1999 Continuation-in-part of Ser. No. US 1999-426571, filed on 22 Oct 1999 Continuation-in-part of Ser. No. US 1999-410568, filed on 1 Oct 1999 Continuation-in-part of Ser. No. US 1999-288594, filed on 8 Apr 1999 Continuation-in-part of Ser. No. US 1998-208277, filed on 8 Dec 1998, now patented, Pat. No. US 6166177		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Ketter, James		
ASSISTANT EXAMINER:	Li, O Janice		
LEGAL REPRESENTATIVE:	Seed Intellectual Property Law Group PLLC		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	10		
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 11 Drawing Page(s)		
LINE COUNT:	11681		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical

compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biological samples.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

INCL INCLM: 514/044.000
 INCLS: 514/002.000; 536/023.100; 530/350.000; 424/093.100;
 424/184.100; 424/185.100; 424/248.100; 424/263.100
 NCL NCLM: 514/044.000
 NCLS: 424/093.100; 424/184.100; 424/185.100; 424/248.100;
 424/263.100; 514/002.000; 530/350.000; 536/023.100

L4 ANSWER 12 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2002:202057 USPATFULL

TITLE: Compounds and methods for treatment and diagnosis of chlamydial infection

INVENTOR(S): Probst, Peter, Seattle, WA, United States
 Bhatia, Ajay, Seattle, WA, United States
 Skeiky, Yasir A. W., Bellevue, WA, United States
 Fling, Steven P., Bainbridge Island, WA, United States

PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, United States
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6432916	B1	20020813
APPLICATION INFO.:	US 2000-556877		20000419 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-454684, filed on 3 Dec 1999 Continuation-in-part of Ser. No. US 1999-426571, filed on 22 Oct 1999 Continuation-in-part of Ser. No. US 1999-410568, filed on 1 Oct 1999 Continuation-in-part of Ser. No. US 1999-288594, filed on 8 Apr 1999 Continuation-in-part of Ser. No. US 1998-208277, filed on 8 Dec 1998		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Ketter, James		
ASSISTANT EXAMINER:	Li, Q Janice		
LEGAL REPRESENTATIVE:	Seed Intellectual Property Law Group PLLC		
NUMBER OF CLAIMS:	22		
EXEMPLARY CLAIM:	22		
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 11 Drawing Page(s)		
LINE COUNT:	9779		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biological samples.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

INCL INCLM: 514/002.000
 INCLS: 424/130.100; 424/184.100; 424/190.100; 536/023.100;
 536/023.400; 435/007.100; 435/975.000
 NCL NCLM: 514/002.000
 NCLS: 424/130.100; 424/184.100; 424/190.100; 435/007.100;
 435/975.000; 536/023.100; 536/023.400

L4 ANSWER 13 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2002:119860 USPATFULL
 TITLE: Compounds and methods for treatment and diagnosis
 of chlamydial infection
 INVENTOR(S): Bhatia, Ajay, Seattle, WA, UNITED STATES
 Skeiky, Yasir A.W., Bellevue, WA, UNITED STATES
 Probst, Peter, Seattle, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002061848	A1	20020523
APPLICATION INFO.:	US 2001-841132	A1	20010423 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-620412, filed on 20 Jul 2000, UNKNOWN		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Page(s)		
LINE COUNT:	5318		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biological samples.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

INCL INCLM: 514/012.000
 INCLS: 530/350.000; 435/069.100; 435/325.000; 435/320.100;
 536/023.100; 435/183.000
 NCL NCLM: 514/012.000
 NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000;
 530/350.000; 536/023.100

(FILE 'CAPLUS, MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,
 JICST-EPLUS, JAPIO, USPATFULL' ENTERED AT 16:18:02 ON 21 JUL 2006)

L5 2229 S "BHATIA A"?/AU
 L6 1292 S "PROBST P"?/AU
 L7 247 S "STROMBERG E"?/AU
 L8 9 S L5 AND L6 AND L7
 L9 45 S L5 AND (L6 OR L7)
 L10 13 S L6 AND L7
 L11 63 S (L9 OR L5 OR L6 OR L7) AND CHLAMYD?
 L12 67 S L8 OR L10 OR L11

Author(s)

L13 30 DUP REM L12 (37 DUPLICATES REMOVED)

L13 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2005:348816 CAPLUS

DOCUMENT NUMBER: 142:405590

TITLE: T cell-stimulating antigens and their encoding nucleic acids for treatment and diagnosis of chlamydial infection

INVENTOR(S): Bhatia, Ajay; Guderian, Jeff; Skeiky, Yasir A. W.; Maisonneuve, Jean-Francois L.

PATENT ASSIGNEE(S): Corixa Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 218 pp., Cont.-in-part of U.S. Ser. No. 7,693.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005084499	A1	20050421	US 2002-197220	20020715
US 6919187	B2	20050719		
US 2003175700	A1	20030918	US 2001-841260	20010423
US 2002146776	A1	20021010	US 2001-7693	20011205
CA 2466043	AA	20030522	CA 2002-2466043	20021105
WO 2003041560	A2	20030522	WO 2002-US35624	20021105
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005232941	A1	20051020	US 2005-109468	20050419
PRIORITY APPLN. INFO.:			US 2000-198853P	P 20000421
			US 2000-219752P	P 20000720
			US 2001-841260	B2 20010423
			US 2001-12256	B2 20011106
			US 2001-7693	A2 20011205
			US 2002-197220	A 20020715
			WO 2002-US35624	W 20021105

AB Compds. and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compds. provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compns. and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent

may be used for the detection of **Chlamydial** infection in patients and in biol. samples.

REFERENCE COUNT: 87 THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 30 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2006:243457 BIOSIS

DOCUMENT NUMBER: PREV200600252004

TITLE: Compounds and methods for treatment and diagnosis of **chlamydial** infection.

AUTHOR(S): **Bhatia, Ajay** [Inventor]; **Guderian, Jeff** [Inventor]; **Skeiky, Yasir A. W.** [Inventor]; **Maisonneuve, Jean-Francois L.** [Inventor]

CORPORATE SOURCE: Seattle, WA USA
ASSIGNEE: Corixa Corporation

PATENT INFORMATION: US 06919187 20050719

SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (JUL 19 2005)
CODEN: OGUPE7. ISSN: 0098-1133.

DOCUMENT TYPE: Patent

LANGUAGE: English

ENTRY DATE: Entered STN: 26 Apr 2006

Last Updated on STN: 26 Apr 2006

AB Compounds and methods for the diagnosis and treatment of **Chlamydial** infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a **Chlamydia** antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of **Chlamydial** infection in patients and in biological samples.

L13 ANSWER 3 OF 30 USPATFULL on STN

ACCESSION NUMBER: 2005:267625 USPATFULL

TITLE: Compounds and methods for treatment and diagnosis of **chlamydial** infection

INVENTOR(S): **Bhatia, Ajay**, Seattle, WA, UNITED STATES
Guderian, Jeff, Lynnwood, WA, UNITED STATES
Skeiky, Yasir A W., Silver Spring, MD, UNITED STATES
Maisonneuve, Jean-Francois L., Federal Way, WA, UNITED STATES

PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005232941	A1	20051020
APPLICATION INFO.:	US 2005-109468	A1	20050419 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-197220, filed on 15 Jul 2002, GRANTED, Pat. No. US 6919187		
	Continuation-in-part of Ser. No. US 2001-7693, filed on 5 Dec 2001, PENDING		
	Continuation-in-part of Ser. No. US 2001-12256, filed on 6 Nov 2001, ABANDONED		
	Continuation-in-part of Ser. No. US 2001-841260, filed on 23 Apr 2001, ABANDONED		

10/762058

10/762058

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-219752P	20000720 (60)
	US 2000-198853P	20000421 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092, US	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4537	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds and methods for the diagnosis and treatment of **Chlamydial** infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a **Chlamydia** antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of **Chlamydial** infection in patients and in biological samples.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 4 OF 30 USPATFULL on STN

ACCESSION NUMBER: 2004:298674 USPATFULL

TITLE: Compounds and methods for treatment and diagnosis of **chlamydial** infection

INVENTOR(S): **Bhatia, Ajay**, Seattle, WA, UNITED STATES
Skeiky, Yasir A.W., Bellevue, WA, UNITED STATES
Probst, Peter, Seattle, WA, UNITED STATES

PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES,
 98104 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004234536	A1	20041125
APPLICATION INFO.:	US 2004-872155	A1	20040618 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-841132, filed on 23 Apr 2001, ABANDONED Continuation-in-part of Ser. No. US 2000-620412, filed on 20 Jul 2000, GRANTED, Pat. No. US 6448234 Continuation-in-part of Ser. No. US 2000-598419, filed on 20 Jun 2000, GRANTED, Pat. No. US 6565856 Continuation-in-part of Ser. No. US 2000-556877, filed on 19 Apr 2000, GRANTED, Pat. No. US 6432916 Continuation-in-part of Ser. No. US 1999-454684, filed on 3 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-426571, filed on 22 Oct 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-410568, filed on 1 Oct 1999, GRANTED, Pat. No. US 6555115 Continuation-in-part of Ser. No. US 1999-288594, filed on 8 Apr 1999, GRANTED, Pat. No. US 6447779 Continuation-in-part of Ser. No. US 1998-208277, filed on 8 Dec 1998, GRANTED, Pat. No. US 6166177		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701		

Searcher : Shears 571-272-2528

FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
 NUMBER OF CLAIMS: 10
 EXEMPLARY CLAIM: CLM-01-18
 NUMBER OF DRAWINGS: 11 Drawing Page(s)
 LINE COUNT: 5306

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds and methods for the diagnosis and treatment of **Chlamydial** infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a **Chlamydia** antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of **Chlamydial** infection in patients and in biological samples.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 5 OF 30 USPATFULL on STN

ACCESSION NUMBER: 2004:177843 USPATFULL
 TITLE: Compounds and methods for treatment and diagnosis of **chlamydial** infection
 INVENTOR(S): **Bhatia, Ajay**, Seattle, WA, UNITED STATES
Probst, Peter, Seattle, WA, UNITED STATES
Stromberg, Erika Jean, Seattle, WA, UNITED STATES
 PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004137007	A1	20040715
APPLICATION INFO.:	US 2004-762058	A1	20040115 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-841260, filed on 23 Apr 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-198853P	20000421 (60)
	US 2000-219752P	20000720 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4173	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds and methods for the diagnosis and treatment of **Chlamydial** infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a **Chlamydia** antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of **Chlamydial** infection in patients and in biological samples.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 6 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2004:1056157 CAPLUS

DOCUMENT NUMBER: 142:54501

TITLE: Differential regulation of inflammatory cytokine secretion by human dendritic cells upon

Chlamydia trachomatis infection

AUTHOR(S): Gervassi, Ana; Alderson, Mark R.; Suchland, Robert; Maisonneuve, Jean Francois; Grabstein, Kenneth H.; **Probst, Peter**

CORPORATE SOURCE: Corixa Corporation, Seattle, WA, USA

SOURCE: Infection and Immunity (2004), 72(12), 7231-7239

CODEN: INFIBR; ISSN: 0019-9567

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB **Chlamydia trachomatis** is an obligate intracellular gram-neg. bacterium responsible for a wide spectrum of diseases in humans. Both genital and ocular **C. trachomatis** infections are associated with tissue inflammation and pathol. Dendritic cells (DC) play an important role in both innate and adaptive immune responses to microbial pathogens and are a source of inflammatory cytokines. To determine the potential contribution of DC to the inflammatory process, human DC were infected with **C. trachomatis** serovar E or L2. Both **C. trachomatis** serovars were found to infect and replicate in DC. Upon infection, DC up-regulated the expression of costimulatory (B7-1) and cell adhesion (ICAM-1) mols. Furthermore, **chlamydial** infection induced the secretion of interleukin-1 β (IL-1 β), IL-6, IL-8, IL-12p70, IL-18, and tumor necrosis factor alpha (TNF- α). The mechanisms involved in **Chlamydia**-induced IL-1 β and IL-18 secretion differed from those of the other cytokines. **Chlamydia**-induced IL-1 β and IL-18 secretion required infection with viable bacteria and was associated with the **Chlamydia**-induced activation of caspase-1 in infected host cells. In contrast, TNF- α and IL-6 secretion did not require that the **Chlamydia** be viable, suggesting that there are at least two mechanisms involved in the **Chlamydia**-induced cytokine secretion in DC. Interestingly, an antibody to Toll-like receptor 4 inhibited **Chlamydia**-induced IL-1 β , IL-6, and TNF- α secretion. The data herein demonstrate that DC can be infected by human **C. trachomatis** serovars and that **chlamydial** components regulate the secretion of various cytokines in DC. Collectively, these data suggest that DC play a role in the inflammatory processes caused by **chlamydial** infections.

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2004:1002331 CAPLUS

DOCUMENT NUMBER: 142:132582

TITLE: Human CD8+ T Cells Recognize the 60-kDa Cysteine-Rich Outer Membrane Protein from **Chlamydia trachomatis**

AUTHOR(S): Gervassi, Ana L.; Grabstein, Kenneth H.; **Probst, Peter**; Hess, Bruce; Alderson, Mark R.; Fling, Steven P.

CORPORATE SOURCE: Corixa, Seattle, WA, 98101, USA

SOURCE: Journal of Immunology (2004), 173(11), 6905-6913

CODEN: JOIMA3; ISSN: 0022-1767

PUBLISHER: American Association of Immunologists
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The intracellular bacterial pathogen **Chlamydia** is sequestered from the host cell cytoplasm by remaining within an inclusion body during its replication cycle. Nevertheless, CD8+ T cells recognizing **Chlamydia** Ags in the context of MHC class I mols. are primed during infection. The authors have recently described derivation of **Chlamydia**-specific human CD8+ T cells by using infected dendritic cells as a surrogate system to reflect **Chlamydia**-specific CD8+ T cell responses in vivo. These CD8+ T cell clones recognize **chlamydial** Ags processed via the conventional class Ia processing pathway, as assessed by treatment of infected APC with lactacystin and brefeldin A, suggesting that the Ags are translocated from the **chlamydial** inclusion into the host cell cytosol. In this study, outer membrane protein 2 (OmcB) was identified as the Ag recognized by one of these **Chlamydia**-specific human CD8+ T cells; and the authors defined the HLA*A0101-restricted epitope from this Ag. CD8+ T cell responses to this epitope were present at high frequencies in the peripheral blood of both of two HLA*A0101 donors tested. In vitro **chlamydial** growth was completely inhibited by the OmcB-specific CD8+ T cell clone independently of lytic mechanisms. OmcB is a 60-kDa protein that has been postulated to be associated with the **Chlamydia** outer membrane complex. The subcellular localization of OmcB to the cytosol of infected cells, as determined by conventional MHC class I Ag processing and presentation, suggests the possibility of an addnl., cytosolic-associated function for this protein.

REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 2003:396648 CAPLUS

DOCUMENT NUMBER: 138:406874

TITLE: Nucleic acids and encoded polypeptides for treatment and diagnosis of **chlamydial** infection

INVENTOR(S): **Bhatia, Ajay**; Guderian, Jeff; Skeiky, Yasir A. W.; Maisonneuve, Jean-Francois L.; Barth, Brenda; **Probst, Peter**

PATENT ASSIGNEE(S): Corixa Corporation, USA

SOURCE: PCT Int. Appl., 275 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003041560	A2	20030522	WO 2002-US35624	20021105
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,			

10/762058

10/762058

BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002146776	A1	20021010	US 2001-7693	20011205
US 2005084499	A1	20050421	US 2002-197220	20020715
US 6919187	B2	20050719		
CA 2466043	AA	20030522	CA 2002-2466043	20021105
PRIORITY APPLN. INFO.:			US 2001-12256	A 20011106
			US 2001-7693	A 20011205
			US 2002-197220	A 20020715
			US 2000-198853P	P 20000421
			US 2000-219752P	P 20000720
			US 2001-841260	A2 20010423
			WO 2002-US35624	W 20021105

AB Comps. and methods for the diagnosis and treatment of **Chlamydial** infection are disclosed. CD4+ T cell expression cloning identified nucleic acids encoding T cell-stimulating antigens from **Chlamydia trachomatis** serovars. The comps. provided include polypeptides that contain at least one antigenic portion of a **Chlamydia** antigen and DNA sequences encoding such polypeptides. Pharmaceutical comps. and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Immunization against **Chlamydia** genital tract infection is demonstrated using the MOMP (major outer membrane protein) from serovar F and the polymorphic membrane proteins G or C (pmpG or pmpC) from serovar L2. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of **Chlamydial** infection in patients and in biol. samples.

L13 ANSWER 9 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 5

ACCESSION NUMBER: 2003:330892 CAPLUS

DOCUMENT NUMBER: 138:352746

TITLE: **Chlamydia trachomatis** antigens, antibodies, and oligonucleotide primers and probes for therapy and diagnosis of **chlamydial** infection

INVENTOR(S): **Probst, Peter; Bhatia, Ajay; Skeiky, Yasir A. W.; Jen, Shyian; Stromberg, Erika Jean**

PATENT ASSIGNEE(S): Corixa Corporation, USA

SOURCE: U.S., 68 pp., Cont.-in-part of U.S. 6,447,779.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6555115	B1	20030429	US 1999-410568	19991001
US 6166177	A	20001226	US 1998-208277	19981208
US 6447779	B1	20020910	US 1999-288594	19990408

Searcher : Shears 571-272-2528

CA 2354232	AA	20000615	CA 1999-2354232	19991208
WO 2000034483	A2	20000615	WO 1999-US29012	19991208
WO 2000034483	A3	20011101		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,				
CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,				
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				
LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU,				
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,				
VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF,				
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1144642	A2	20011017	EP 1999-963037	19991208
EP 1144642	A3	20020605		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,				
PT, IE, SI, LT, LV, FI, RO				
BR 9916020	A	20020122	BR 1999-16020	19991208
TR 200102500	T2	20020321	TR 2001-200102500	19991208
JP 2002531129	T2	20020924	JP 2000-586916	19991208
NZ 512246	A	20031219	NZ 1999-512246	19991208
AU 769293	B2	20040122	AU 2000-19358	19991208
US 6432916	B1	20020813	US 2000-556877	20000419
US 6565856	B1	20030520	US 2000-598419	20000620
US 6448234	B1	20020910	US 2000-620412	20000720
NO 2001002812	A	20010802	NO 2001-2812	20010607
AU 2004201702	A1	20040520	AU 2004-201702	20040422
US 2004234536	A1	20041125	US 2004-872155	20040618
PRIORITY APPLN. INFO.:			US 1998-208277	A2 19981208

US 1999-288594	A2 19990408
US 1999-410568	A 19991001
US 1999-426571	A 19991022
US 1999-454684	A2 19991203
WO 1999-US29012	W 19991208
US 2000-556877	A2 20000419
US 2000-598419	A2 20000620
US 2000-620412	A2 20000720
US 2001-841132	A1 20010423

AB Compds. and methods for the diagnosis and treatment of **Chlamydial** infection are disclosed. The compds. provided include polypeptides that contain at least one antigenic portion of a **Chlamydia** antigen and DNA sequences encoding such polypeptides. Pharmaceutical compns. and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of **Chlamydial** infection in patients and in biol. samples.

REFERENCE COUNT: 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 10 OF 30 USPATFULL on STN

ACCESSION NUMBER: 2003:250914 USPATFULL
TITLE: Compounds and methods for treatment and diagnosis
of **chlamydial** infection
INVENTOR(S): **Bhatia, Ajay**, Seattle, WA, UNITED STATES
Probst, Peter, Seattle, WA, UNITED STATES
Stromberg, Erika Jean, Seattle, WA,
UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175700	A1	20030918
APPLICATION INFO.:	US 2001-841260	A1	20010423 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-198853P	20000421 (60)
	US 2000-219752P	20000720 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	9573	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds and methods for the diagnosis and treatment of
Chlamydial infection are disclosed. The compounds provided
include polypeptides that contain at least one antigenic portion of
a **Chlamydia** antigen and DNA sequences encoding such
polypeptides. Pharmaceutical compositions and vaccines comprising
such polypeptides or DNA sequences are also provided, together with
antibodies directed against such polypeptides. Diagnostic kits
containing such polypeptides or DNA sequences and a suitable
detection reagent may be used for the detection of
Chlamydial infection in patients and in biological samples.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 6

ACCESSION NUMBER: 2003:787755 CAPLUS
DOCUMENT NUMBER: 139:306396
TITLE: Functional characterization of class Ia- and
non-class Ia-restricted **chlamydia**
-reactive CD8+ T cell responses in humans
AUTHOR(S): **Gervassi, Ana L.**; **Probst, Peter**; **Stamm,**
Walter E.; **Marrazzo, Jeanne**; **Grabstein, Kenneth**
H.; **Alderson, Mark R.**
CORPORATE SOURCE: Corixa Corporation, Seattle, WA, 98104, USA
SOURCE: Journal of Immunology (2003), 171(8), 4278-4286
CODEN: JOIMA3; ISSN: 0022-1767
PUBLISHER: American Association of Immunologists
DOCUMENT TYPE: Journal
LANGUAGE: English

AB CD8+ T cells are a key immune component for the eradication of many
intracellular pathogens. This study aims to characterize the human
CD8+ T cell response to naturally processed **chlamydial** Ags
in individuals exposed to the intracellular pathogen **Chlamydia**
trachomatis. By using C. trachomatis-infected autologous dendritic

cells (DCs) as stimulators, **Chlamydia**-reactive CD8+ T cell responses were detected in all 10 individuals tested. The majority of the **Chlamydia**-reactive CD8+ T cells were non-MHC class Ia restricted in all three of the individuals tested. From one donor, three non-class Ia-restricted and two class Ia-restricted **Chlamydia**-specific CD8+ T cells were cloned and characterized further. All five T cell clones secreted IFN- γ in response to autologous DCs infected with viable **Chlamydia**, but not with DCs pulsed with inactivated **chlamydial** elementary bodies. MHC class Ia-restricted and non-class Ia-restricted responses were inhibited by DC treatment with a proteasomal inhibitor and an endoplasmic reticulum-Golgi transport inhibitor, suggesting that these T cells recognize a peptide Ag translocated to the host cell cytosol during infection that is processed via the classical class Ia Ag-processing pathway. Even though both restricted and nonrestricted CD8+ T cells produced IFN- γ in response to **Chlamydia**-infected fibroblasts, only the non-class Ia-restricted cells were lytic for these targets. The class Ia-restricted CTLs, however, were capable of cytolysis as measured by redirected killing. Collectively, these data demonstrate that both class Ia-restricted and non-classically restricted CD8+ T cells are elicited in *C. trachomatis*-exposed individuals. Their role in host immunity remains to be elucidated.

REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 12 OF 30 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2003:519164 BIOSIS

DOCUMENT NUMBER: PREV200300520633

TITLE: A non-replicative whole cell vaccine provides heterologous protection against murine genital infection by **Chlamydia** trachomatis serovar K.

AUTHOR(S): Barth, B. D. [Reprint Author]; Probst, P. [Reprint Author]; Verlant, V.; Grabstein, K. [Reprint Author]; Dalemans, W.; Fang, H. [Reprint Author]; Gervassi, A. [Reprint Author]; Lobet, Y.; Maisonneuve, J. [Reprint Author]

CORPORATE SOURCE: Corixa Corporation, Seattle, WA, USA

SOURCE: Abstracts of the General Meeting of the American Society for Microbiology, (2003) Vol. 103, pp. D-179. <http://www.asmta.org/mtgsrc/generalmeeting.htm>. cd-rom. Meeting Info.: 103rd American Society for Microbiology General Meeting. Washington, DC, USA. May 18-22, 2003. American Society for Microbiology. ISSN: 1060-2011 (ISSN print).

DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 5 Nov 2003

Last Updated on STN: 5 Nov 2003

AB Background: A vaccine against **Chlamydia** trachomatis would constitute the ultimate tool to control the asymptomatic sexually transmitted diseases associated with this bacterium. Methods: Mice were infected vaginally with a serovar K strain, in order to mimic the human disease. UV-inactivated elementary bodies (UEB) combined with a novel GlaxoSmithKline adjuvant system (SBAS1) were used to immunize against infection. In order to study the mechanisms of

protection: i. T-cells were depleted in UVEB immunized mice before and during challenge; ii. splenocytes were transferred from UVEB-mice to lymphocyte-deficient (RAG1) mice just before infection, iii. B-cell-deficient mice were immunized with UVEB and then infected. Results: The model resembled the human disease, showing **chlamydial** shedding and endometritis. Immunization with UVEB serovar K or E resulted in protection against colonization and disease. CD4+ T depletion of the vaccinees markedly reduced shedding at day 4 post infection; however, at day 7, protection was restored, suggesting a second protective mechanism. CD3-enriched splenocytes transfer from UVEB-vaccinated mice to RAG1 mice just before infection conferred protection against infection when compared to transfer of splenocytes from sham-immunized control mice. Finally, UVEB immunization of B-cell-deficient mice also resulted in full protection against infection. Conclusion: The data show that T-cell based immune protection against *C. trachomatis* can be obtained with non-replicative, systemic vaccines and suggest that a similar result could be reached with a sub-unit vaccine formulated in the proper adjuvant and eliciting the appropriate T cell response.

L13 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 7

ACCESSION NUMBER: 2002:90085 CAPLUS
DOCUMENT NUMBER: 136:166047
TITLE: Compounds and methods for treatment and diagnosis of **Chlamydial** infection
INVENTOR(S): Fling, Steven P.; Skeiky, Yasir A. W.;
Probst, Peter; Bhatia, Ajay
PATENT ASSIGNEE(S): Corixa Corporation, USA
SOURCE: PCT Int. Appl., 537 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008267	A2	20020131	WO 2001-US23121	20010720
WO 2002008267	A3	20030227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 6448234	B1	20020910	US 2000-620412	20000720
US 2002061848	A1	20020523	US 2001-841132	20010423
CA 2418282	AA	20020131	CA 2001-2418282	20010720
EP 1307564	A2	20030507	EP 2001-959114	20010720
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012602	A	20040217	BR 2001-12602	20010720
JP 2004513622	T2	20040513	JP 2002-514171	20010720
NZ 523628	A	20050826	NZ 2001-523628	20010720
NO 2003000252	A	20030314	NO 2003-252	20030117
PRIORITY APPLN. INFO.:			US 2000-620412	A 20000720

US 2001-841132	A 20010423
US 1998-208277	A2 19981208
US 1999-288594	A2 19990408
US 1999-410568	A2 19991001
US 1999-426571	A2 19991022
US 1999-454684	A2 19991203
US 2000-556877	A2 20000419
US 2000-598419	A2 20000620
WO 2001-US23121	W 20010720

AB Compds. and methods for the diagnosis and treatment of **Chlamydial** infection are disclosed. The compds. provided include polypeptides that contain at least one antigenic portion of a **Chlamydia** antigen and DNA sequences encoding such polypeptides. Pharmaceutical compns. and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of **Chlamydial** infection in patients and in biol. samples.

L13 ANSWER 14 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 8

ACCESSION NUMBER: 2003:1003400 CAPLUS

Correction of: 2002:778631

DOCUMENT NUMBER: 140:1601

Correction of: 137:290038

TITLE: Nucleic acids and proteins from **Chlamydia** trachomatis and methods for treatment and diagnosis of **chlamydial** infection

INVENTOR(S): **Bhatia, Ajay; Probst, Peter**

PATENT ASSIGNEE(S): Corixa Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 42 pp., Cont.-in-part of U.S. Ser. No. 841,260.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002146776	A1	20021010	US 2001-7693	20011205
US 2003175700	A1	20030918	US 2001-841260	20010423
US 2005084499	A1	20050421	US 2002-197220	20020715
US 6919187	B2	20050719		
CA 2466043	AA	20030522	CA 2002-2466043	20021105
WO 2003041560	A2	20030522	WO 2002-US35624	20021105

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,

10/762058

NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
 TM, TN, TR, TT, TZ, UA, UG, US, VZ, VC, VN, YU, ZA, ZM, ZW,
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004137007 A1 20040715 US 2004-762058 20040115
 US 2005232941 A1 20051020 US 2005-109468 20050419
 PRIORITY APPLN. INFO.: US 2000-198853P P 20000421

US 2000-219752P P 20000720

US 2001-841260 A2 20010423

US 2001-12256 B2 20011106

US 2001-7693 A2 20011205

US 2002-197220 A 20020715

WO 2002-US35624 W 20021105

AB Nucleic acid and protein compds. and methods for the diagnosis and treatment of **chlamydial** infection are disclosed. The compds. provided include polypeptides that contain at least one antigenic portion of a **Chlamydia** antigen and genomic DNA sequences encoding such polypeptides from *C. trachomatis* serovar E and serovar D. Pharmaceutical compns. and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of **chlamydial** infection in patients and in biol. samples.

L13 ANSWER 15 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 9

ACCESSION NUMBER: 2002:392223 CAPLUS

DOCUMENT NUMBER: 136:397052

TITLE: Compounds and methods for treatment and diagnosis of **Chlamydial** infection

INVENTOR(S): **Bhatia, Ajay**; Skeiky, Yasir A. W.; **Probst, Peter**

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 66 pp., Cont.-in-part of U.S. Ser. No. 620,412.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002061848	A1	20020523	US 2001-841132	20010423
US 6448234	B1	20020910	US 2000-620412	20000720
CA 2418282	AA	20020131	CA 2001-2418282	20010720
WO 2002008267	A2	20020131	WO 2001-US23121	20010720
WO 2002008267	A3	20030227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,

Searcher : Shears 571-272-2528

10/762058

LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
 NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
 TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
 TD, TG

EP 1307564	A2	20030507	EP 2001-959114	20010720
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012602	A	20040217	BR 2001-12602	20010720
JP 2004513622	T2	20040513	JP 2002-514171	20010720
NZ 523628	A	20050826	NZ 2001-523628	20010720
NO 2003000252	A	20030314	NO 2003-252	20030117
US 2004234536	A1	20041125	US 2004-872155	20040618
PRIORITY APPLN. INFO.:			US 2000-620412	A2 20000720

US 1998-208277	A2 19981208
US 1999-288594	A2 19990408
US 1999-410568	A2 19991001
US 1999-426571	A2 19991022
US 1999-454684	A2 19991203
US 2000-556877	A2 20000419
US 2000-598419	A2 20000620
US 2001-841132	A 20010423
WO 2001-US23121	W 20010720

AB Compds. and methods for the diagnosis and treatment of **Chlamydial** infection are disclosed. The compds. provided include polypeptides that contain at least one antigenic portion of a **Chlamydia** antigen and DNA sequences encoding such polypeptides. Pharmaceutical compns. and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of **Chlamydial** infection in patients and in biol. samples. Compds. and methods for the diagnosis and treatment of **Chlamydial** infection are disclosed. The compds. provided include polypeptides that contain at least one antigenic portion of a **Chlamydia** antigen and DNA sequences encoding such polypeptides. Pharmaceutical compns. and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of **Chlamydial** infection in patients and in biol. samples.

L13 ANSWER 16 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 10
 ACCESSION NUMBER: 2002:688472 CAPLUS
 DOCUMENT NUMBER: 137:231341
 TITLE: **Chlamydia** antigens for treatment and
 diagnosis of **Chlamydial** infection

Searcher : Shears 571-272-2528

INVENTOR(S) : Probst, Peter; Bhatia, Ajay;
 Skeiky, Yasir A. W.; Fling, Steven P.
 PATENT ASSIGNEE(S) : Corixa Corporation, USA
 SOURCE: U.S., 34 pp., Cont.-in-part of U.S. 6,166,177.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 9
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6447779	B1	20020910	US 1999-288594	19990408
US 6166177	A	20001226	US 1998-208277	19981208
US 6555115	B1	20030429	US 1999-410568	19991001
CA 2354232	AA	20000615	CA 1999-2354232	19991208
WO 2000034483	A2	20000615	WO 1999-US29012	19991208
WO 2000034483	A3	20011101		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1144642	A2	20011017	EP 1999-963037	19991208
EP 1144642	A3	20020605		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9916020	A	20020122	BR 1999-16020	19991208
TR 200102500	T2	20020321	TR 2001-200102500	19991208
JP 2002531129	T2	20020924	JP 2000-586916	19991208
NZ 512246	A	20031219	NZ 1999-512246	19991208
AU 769293	B2	20040122	AU 2000-19358	19991208
US 6432916	B1	20020813	US 2000-556877	20000419
US 6565856	B1	20030520	US 2000-598419	20000620
US 6448234	B1	20020910	US 2000-620412	20000720
ZA 2001004414	A	20020829	ZA 2001-4414	20010529
NO 2001002812	A	20010802	NO 2001-2812	20010607
AU 2004201702	A1	20040520	AU 2004-201702	20040422
US 2004234536	A1	20041125	US 2004-872155	20040618
PRIORITY APPLN. INFO.:			US 1998-208277	A2 19981208
			US 1999-288594	A2 19990408
			US 1999-410568	A 19991001
			US 1999-426571	A 19991022
			US 1999-454684	A2 19991203
			WO 1999-US29012	W 19991208
			US 2000-556877	A2 20000419
			US 2000-598419	A2 20000620
			US 2000-620412	A2 20000720

AB Compds. and methods for the diagnosis and treatment of **Chlamydial** infection are disclosed. The compds. provided include polypeptides that contain at least one antigenic portion of a **Chlamydia** antigen and DNA sequences encoding such polypeptides. Pharmaceutical compns. and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of **Chlamydial** infection in patients and in biol. samples.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 17 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 11

ACCESSION NUMBER: 2002:609966 CAPLUS

DOCUMENT NUMBER: 137:168258

TITLE: **Chlamydia** antigens or fragments and oligonucleotide probes and primers for treatment and diagnosis of **chlamydial** infection

INVENTOR(S): **Probst, Peter; Bhatia, Ajay; Skeiky, Yasir A. W.; Fling, Steven P.**

PATENT ASSIGNEE(S): Corixa Corporation, USA

SOURCE: U.S., 194 pp., Cont. of U.S. Ser. No. 454,684. CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6432916	B1	20020813	US 2000-556877	20000419
US 6166177	A	20001226	US 1998-208277	19981208
US 6447779	B1	20020910	US 1999-288594	19990408
US 6555115	B1	20030429	US 1999-410568	19991001
US 6565856	B1	20030520	US 2000-598419	20000620
US 6448234	B1	20020910	US 2000-620412	20000720
CA 2390088	AA	20010607	CA 2000-2390088	20001204
WO 2001040474	A2	20010607	WO 2000-US32919	20001204
WO 2001040474	A3	20020307		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1238084	A2	20020911	EP 2000-980969	20001204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003515343	T2	20030507	JP 2001-542539	20001204
BR 2000016066	A	20030610	BR 2000-16066	20001204
NZ 518917	A	20040625	NZ 2000-518917	20001204
ZA 2002004359	A	20030901	ZA 2002-4359	20020530

10/762058

NO 2002002592	A	20020719	NO 2002-2592	20020531
US 2004234536	A1	20041125	US 2004-872155	20040618
PRIORITY APPLN. INFO.:			US 1998-208277	A2 19981208
			US 1999-288594	A2 19990408
			US 1999-410568	A2 19991001
			US 1999-426571	A2 19991022
			US 1999-454684	A2 19991203
			US 2000-556877	A2 20000419
			US 2000-598419	A2 20000620
			US 2000-620412	A2 20000720
			WO 2000-US32919	W 20001204
			US 2001-841132	A1 20010423

AB Compds. and methods for the diagnosis and treatment of **Chlamydial** infection are disclosed. The compds. provided include polypeptides that contain at least one antigenic portion of a **Chlamydia** antigen and DNA sequences encoding such polypeptides. Pharmaceutical compns. and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of **Chlamydial** infection in patients and in biol. samples.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 12

ACCESSION NUMBER: 2002:749658 CAPLUS

DOCUMENT NUMBER: 138:22880

TITLE: **Chlamydial** antigens colocalize within IncA-laden fibers extending from the inclusion membrane into the host cytosol

AUTHOR(S): Brown, W. J.; Skeiky, Y. A. W.; Probst, P.; Rockey, D. D.

CORPORATE SOURCE: Department of Microbiology, Oregon State University, Corvallis, OR, 97331, USA

SOURCE: Infection and Immunity (2002), 70(10), 5860-5864
CODEN: INFIBR; ISSN: 0019-9567

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB **Chlamydial** IncA localizes to the inclusion membrane and to vesicular fibers extending away from the inclusion. **Chlamydial** outer membrane components, in the absence of developmental forms, are found within these fibers. This colocalization may explain how **chlamydial** developmental form antigens are localized outside of the inclusion within infected cells.

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 19 OF 30 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation
on STN

ACCESSION NUMBER: 2002:613047 SCISEARCH

THE GENUINE ARTICLE: 574VC

TITLE: Helicobacter pylori-induced activation of human
endothelial cells

AUTHOR: Innocenti M (Reprint); Thoreson A C; Ferrero R L;
Stromberg E; Bolin I; Eriksson L; Svennerholm
A M; Quiding-Jarbrink M

CORPORATE SOURCE: Gothenburg Univ, Dept Rheumatol & Inflamm Res,
Guldhedsgatan 10 A, S-41346 Gothenburg, Sweden
(Reprint); Gothenburg Univ, Sahlgrenska Acad, Dept Med
Microbiol & Immunol, S-41346 Gothenburg, Sweden;
Swedish Inst Infect Dis Control, Dept Bacteriol,
Stockholm, Sweden; Inst Pasteur, Unite Pathogenie
Bacterienne Muqueuses, F-75724 Paris, France

COUNTRY OF AUTHOR: Sweden; France

SOURCE: INFECTION AND IMMUNITY, (AUG 2002) Vol. 70, No. 8, pp.
4581-4590.

ISSN: 0019-9567.

PUBLISHER: AMER SOC MICROBIOLOGY, 1752 N ST NW, WASHINGTON, DC
20036-2904 USA.

DOCUMENT TYPE: Article; Journal

LANGUAGE: English

REFERENCE COUNT: 56

ENTRY DATE: Entered STN: 9 Aug 2002

Last Updated on STN: 9 Aug 2002

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Helicobacter pylori infection causes active chronic inflammation
with a continuous recruitment of neutrophils to the inflamed gastric
mucosa. To evaluate the role of endothelial cells in this process, we
have examined adhesion molecule expression and chemokine and cytokine
production from human umbilical vein endothelial cells stimulated with
well-characterized H. pylori strains as well as purified proteins.
Our results indicate that endothelial cells actively contribute to
neutrophil recruitment, since stimulation with H. pylori bacteria
induced upregulation of the adhesion molecules VCAM-1, ICAM-1, and
E-selectin as well as the chemokines interleukin 8 (IL-8) and
growth-related oncogene alpha (GRO-alpha) and the cytokine IL-6.
However, there were large variations in the ability of the different
H. pylori strains to stimulate endothelial cells. These interstrain
variations were seen irrespective of whether the strains had been
isolated from patients with duodenal ulcer disease or asymptomatic
carriers and were not solely related to the expression of known
virulence factors, such as the cytotoxin-associated gene pathogenicity
island, vacuolating toxin A, and Lewis blood group antigens. In
addition, one or several unidentified proteins which act via NF-kappaB
activation seem to induce endothelial cell activation. In conclusion,
human endothelial cells produce neutrophil-recruiting factors and show
increased adhesion molecule expression after stimulation with certain
H. pylori strains. These effects probably contribute to the
continuous recruitment of neutrophils to H. pylori-infected gastric
mucosa and may also contribute to tissue damage and ulcer formation.

L13 ANSWER 20 OF 30 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN

ACCESSION NUMBER: 2002443492 EMBASE

TITLE: Findings from STD screening of adolescents and adults
entering corrections facilities: Implications for STD

control strategies.

AUTHOR: Mertz K.J.; Voigt R.A.; Hutchins K.; Levine W.C.; Dyer I.; Rollin L.D.; Kent C.K.; Kohn R.P.; Courtney J.; Montes J.; Miller J.; Gilson D.; Chow J.; Neylans L.; Blank S.; Whelan M.; Powers P.; Outlin T.; Schwebke J.; Beidinger H.A.; Evens A.; Mayfield J.; Hutcheson D.; Spaulding A.; Jackson E.; Mangiameli E.; Byrnes J.; Barrow R.; Jinks R.; Bhatia A.; Panda P.; Fox A.

CORPORATE SOURCE: Dr. K.J. Mertz, Georgia Division of Public Health, 2 Peachtree Street NW, Atlanta, GA 30303, United States. kjmertz@dhr.state.ga.us

SOURCE: Sexually Transmitted Diseases, (1 Dec 2002) Vol. 29, No. 12, pp. 834-839. .
Refs: 12
ISSN: 0148-5717 CODEN: STRDDM

COUNTRY: United States

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 004 Microbiology
017 Public Health, Social Medicine and Epidemiology

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 27 Dec 2002
Last Updated on STN: 27 Dec 2002

AB Background: Persons entering corrections facilities are at high risk for sexually transmitted diseases (STDs) because of risky sexual behavior and lack of access to routine screening. Goal: The goal of the study was to develop a national picture of STD prevalence in this population. Study Design: We analyzed information on age, race/ethnicity, urethral symptoms (men only), and test results for approximately 85,000 **chlamydia**, 157,000 gonorrhea, and 293,000 syphilis tests for persons entering 23 jails and 12 juvenile detention centers in 13 US counties from 1996 through 1999. Results: At adult jails in nine counties, the median percentage of persons with reactive syphilis tests by county was 8.2% (range, 0.3-23.8%) for women and 2.5% (range, 1.0-7.8%) for men. At juvenile detention facilities in five counties, the median positivity for **chlamydial** infection was 15.6% (range, 8.0- 19.5%) for adolescent girls and 7.6% (range, 2.8-8.9%) for adolescent boys; the median positivity for gonorrhea was 5.2% (range, 3.4-10.0%) for adolescent girls and 0.9% (range, 0.7-2.6%) for adolescent boys. Of adolescent boys testing positive for **chlamydial** infection at three juvenile facilities, approximately 97% did not report symptoms; of adolescent boys positive for gonorrhea, 93% did not report symptoms. Conclusion: STD positivity among persons entering corrections facilities is high. Most **chlamydial** and gonococcal infections are asymptomatic and would not be detected without routine screening. Monitoring the prevalence of STDs in this population is useful for planning STD prevention activities in corrections facilities and elsewhere in the community.

L13 ANSWER 21 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 13

ACCESSION NUMBER: 2001:798255 CAPLUS

DOCUMENT NUMBER: 135:343284

TITLE: Antigenic protein and DNA compounds and methods for treatment and diagnosis of **chlamydial** infection

INVENTOR(S): Bhatia, Ajay; Probst, Peter; Stromberg, Erika Jean

PATENT ASSIGNEE(S): Corixa Corporation, USA

SOURCE: PCT Int. Appl., 208 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081379	A2	20011101	WO 2001-US13081	20010423
WO 2001081379	A3	20020919		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2407114	AA	20011101	CA 2001-2407114	20010423
EP 1278855	A2	20030129	EP 2001-928775	20010423
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2000-198853P P 20000421
 US 2000-219752P P 20000720
 WO 2001-US13081 W 20010423

AB Comps. and methods for the diagnosis and treatment of **chlamydial** infection are disclosed. The comps. provided include polypeptides that contain at least one antigenic portion of a **Chlamydia trachomatis** antigen and DNA sequences encoding such polypeptides. Pharmaceutical comps. and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of **chlamydial** infection in patients and in biol. samples.

L13 ANSWER 22 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 14
 ACCESSION NUMBER: 2001:417155 CAPLUS
 DOCUMENT NUMBER: 135:45174
 TITLE: Antigenic compounds and methods for treatment and diagnosis of **Chlamydial** infection
 INVENTOR(S): **Probst, Peter; Bhatia, Ajay;**
 Skeiky, Yasir A. W.; Fling, Steven P.; Scholler, John
 PATENT ASSIGNEE(S): Corixa Corporation, USA
 SOURCE: PCT Int. Appl., 293 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 9
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001040474	A2	20010607	WO 2000-US32919	20001204

WO 2001040474 A3 20020307
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 US 6432916 B1 20020813 US 2000-556877 20000419
 US 6565856 B1 20030520 US 2000-598419 20000620
 CA 2390088 AA 20010607 CA 2000-2390088 20001204
 EP 1238084 A2 20020911 EP 2000-980969 20001204
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2003515343 T2 20030507 JP 2001-542539 20001204
 BR 2000016066 A 20030610 BR 2000-16066 20001204
 NZ 518917 A 20040625 NZ 2000-518917 20001204
 ZA 2002004359 A 20030901 ZA 2002-4359 20020530
 NO 2002002592 A 20020719 NO 2002-2592 20020531
 PRIORITY APPLN. INFO.: US 1999-454684 A 19991203

US 2000-556877 A 20000419

US 2000-598419 A 20000620

US 1998-208277 A2 19981208

US 1999-288594 A2 19990408

US 1999-410568 A2 19991001

US 1999-426571 A2 19991022

WO 2000-US32919 W 20001204

AB Comps. and methods for the diagnosis and treatment of **Chlamydial** infection are disclosed. The comps. provided include polypeptides that contain at least one antigenic portion of a **Chlamydia** antigen and DNA sequences encoding such polypeptides from **Chlamydia trachomatis** and *C. pneumoniae* isolated using retroviral expression vector systems and subsequent immunol. anal. and epitope mapping. Pharmaceutical comps. and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of **Chlamydial** infection in patients and in biol. samples. In particular, fusion proteins are constructed from the **Chlamydial** proteins PmpA, PmpF, PmpH, PmpB, and PmpC fused with amino acid residues 192-323 of the Ra2 MTB32A serine proteinase from *Mycobacterium tuberculosis*.

L13 ANSWER 23 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 15

ACCESSION NUMBER: 2001:120546 CAPLUS

DOCUMENT NUMBER: 134:325125

TITLE: CD8+ T cells recognize an inclusion membrane-associated protein from the vacuolar pathogen **Chlamydia trachomatis**

AUTHOR(S): Fling, Steven P.; Sutherland, R. Alec; Steele,

Lisa N.; Hess, Bruce; D'Orazio, Sarah E. F.;
 Maisonneuve, Jean-Francois; Lampe, Mary F.;
Probst, Peter; Starnbach, Michael N.
 CORPORATE SOURCE: Corixa Corporation, Seattle, WA, 98104, USA
 SOURCE: Proceedings of the National Academy of Sciences of
 the United States of America (2001), 98(3),
 1160-1165
 CODEN: PNASA6; ISSN: 0027-8424
 PUBLISHER: National Academy of Sciences
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB During infection with *Chlamydia trachomatis*, CD8+ T cells
 are primed, even though the bacteria remain confined to a host cell
 vacuole throughout their developmental cycle. Because CD8+ T cells
 recognize antigens processed from cytosolic proteins, the
Chlamydia antigens recognized by these CD8+ T cells very
 likely have access to the host cell cytoplasm during infection. The
 identity of these *C. trachomatis* proteins has remained elusive, even
 though their localization suggests they may play important roles in
 the biol. of the organism. Here we use a retroviral expression system
 to identify Cap1, a 31-kDa protein from *C. trachomatis* recognized by
 protective CD8+ T cells. Cap1 contains no strong homol. to any known
 protein. Immunofluorescence microscopy by using Cap1-specific
 antibody demonstrates that this protein is localized to the vacuolar
 membrane. Cap1 is virtually identical among the human *C. trachomatis*
 serovars, suggesting that a vaccine incorporating Cap1 might enable
 the vaccine to protect against all *C. trachomatis* serovars. The
 identification of proteins such as Cap1 that associate with the inclusion
 membrane will be required to fully understand the interaction of *C.*
trachomatis with its host cell.

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE
 RE FORMAT

L13 ANSWER 24 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 16
 ACCESSION NUMBER: 2001:26338 CAPLUS
 DOCUMENT NUMBER: 134:206303
 TITLE: Identification and characterization of T
 cell-stimulating antigens from *Leishmania* by CD4 T
 cell expression cloning
 AUTHOR(S): **Probst, Peter**; **Stromberg, Erika**
 ; Ghalib, Hashim W.; Mozel, Michelle; Badaro,
 Roberto; Reed, Steven G.; Webb, John R.
 CORPORATE SOURCE: Corixa Corporation, Seattle, WA, 98104, USA
 SOURCE: Journal of Immunology (2001), 166(1), 498-505
 CODEN: JOIMA3; ISSN: 0022-1767
 PUBLISHER: American Association of Immunologists
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Persistent immunity against *Leishmania* infections in humans is
 mediated predominantly by CD4+ T cells of the Th1 phenotype. Herein
 we report the expression cloning of eight *Leishmania* Ags using
 parasite-specific T cell lines derived from an immune donor. The Ags
 identified by this technique include the flagellar proteins α -
 and β -tubulin, histone H2b, ribosomal protein S4, malate
 dehydrogenase, and elongation factor 2, as well as two novel parasite
 proteins. None of these proteins have been previously reported as T
 cell-Stimulating Ags from *Leishmania*. β -Tubulin-specific T cell
 clones generated against *Leishmania* major amastigotes responded to
Leishmania-infected macrophages and dendritic cells. IFN- γ

enzyme-linked immunospot anal. demonstrated the presence of T cells specific for several of these Ags in PBMC from self-healing cutaneous leishmaniasis patients infected with either *Leishmania tropica* or *L. major*. The responses elicited by *Leishmania* histone H2b were particularly striking in terms of frequency of histone-specific T cells in PBMC (1 T cell of 6000 PBMC) as well as the percentage of responding donors (86%, 6 of 7). Ags identified by T cells from immune donors might constitute potential vaccine candidates for leishmaniasis.

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 25 OF 30 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2002:223214 BIOSIS

DOCUMENT NUMBER: PREV200200223214

TITLE: Discovery of new vaccine candidates for prevention and treatment of *Chlamydia*.

AUTHOR(S): Jen, S. S. [Reprint author]; Stromberg, E. J. [Reprint author]; Probst, P. [Reprint author]; Bhatia, A. [Reprint author]; Skeiky, Y. A. W. [Reprint author]

CORPORATE SOURCE: Corixa Corp, Seattle, WA, USA

SOURCE: Abstracts of the General Meeting of the American Society for Microbiology, (2001) Vol. 101, pp. 343. print.
Meeting Info.: 101st General Meeting of the American Society for Microbiology. Orlando, FL, USA. May 20-24, 2001. American Society of Microbiology.
ISSN: 1060-2011.

DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 3 Apr 2002

Last Updated on STN: 3 Apr 2002

AB *Chlamydia* is one of the most common sexually transmitted diseases. It affects 162 million people, with 90 million new infections occurring annually (WHO, 1996). Limiting to the timely detection of exposure is that *C. trachomatis* (CT) infections can be asymptomatic for an extended period of time and typically, worse pathology has been associated with prolonged infection. Sequelae to *chlamydial* infection are attributed to previous infection and thought to be the result of the host inflammatory response. Standard treatment for *chlamydial* infection is with antibiotics. However, clearance of previous infection following antibiotic treatment does not confer complete immunity to re-infection. Therefore, current efforts are directed towards the development of an effective vaccine. While it is apparent that most infected individuals mount both humoral and cell mediated immune responses, it is not clear how much each contribute to clearance of infection and development of protective immunity. Thus a two-pronged approach was taken to identify potential antigens as possible vaccine candidates. A randomly sheared genomic CT (LGVII serovar) expression library was screened with pooled sera from five CT infected individuals using a secondary antibody to human IgG,A,M. Strongly immunoreactive clones were arrayed on a 96-well microtiter plate and evaluated on CD4+ T cell lines generated from CT infected individuals. By this method we identified several distinct serological clones, of which some were shown to be positive for proliferation and production of IFNgamma.

Consequently, we have identified potential vaccine targets that elicit both an antibody as well as a T cell response. The full-length sequences of these clones have been prioritized for subsequent evaluation in animal models of **Chlamydia**.

L13 ANSWER 26 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 17

ACCESSION NUMBER: 2000:402007 CAPLUS

DOCUMENT NUMBER: 133:53686

TITLE: **Chlamydial antigens and genomic DNA sequences for treatment and diagnosis of chlamydial infection**

INVENTOR(S): **Probst, Peter; Bhatia, Ajay; Skeiky, Yasir A. W.; Fling, Steven P.; Jen, Shyian; Stromberg, Erica Jean**

PATENT ASSIGNEE(S): Corixa Corporation, USA

SOURCE: PCT Int. Appl., 256 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000034483	A2	20000615	WO 1999-US29012	19991208
WO 2000034483	A3	20011101		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6166177	A	20001226	US 1998-208277	19981208
US 6447779	B1	20020910	US 1999-288594	19990408
US 6555115	B1	20030429	US 1999-410568	19991001
CA 2354232	AA	20000615	CA 1999-2354232	19991208
EP 1144642	A2	20011017	EP 1999-963037	19991208
EP 1144642	A3	20020605		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9916020	A	20020122	BR 1999-16020	19991208
JP 2002531129	T2	20020924	JP 2000-586916	19991208
NZ 512246	A	20031219	NZ 1999-512246	19991208
AU 769293	B2	20040122	AU 2000-19358	19991208
NO 2001002812	A	20010802	NO 2001-2812	20010607
AU 2004201702	A1	20040520	AU 2004-201702	20040422
PRIORITY APPLN. INFO.:			US 1998-208277	A 19981208
			US 1999-288594	A 19990408
			US 1999-410568	A 19991001
			US 1999-426571	A 19991022
			WO 1999-US29012	W 19991208

AB Compds. and methods for the diagnosis and treatment of

Chlamydial infection are disclosed. The compds. provided include polypeptides that contain at least one antigenic portion of a **Chlamydia** antigen and DNA sequences encoding such polypeptides. **Chlamydia** antigens were isolated by expression cloning of a genomic DNA library of *C. trachomatis* LGV II, and shown to induce T cell proliferation and interferon- β production. Immune responses of human PBMC and T cell lines are generated against the **Chlamydia** antigens. Pharmaceutical compns. and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of **Chlamydial** infection in patients and in biol. samples.

L13 ANSWER 27 OF 30 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation
on STN DUPLICATE 18

ACCESSION NUMBER: 2001:292665 BIOSIS
DOCUMENT NUMBER: PREV200100292665
TITLE: Compounds and methods for the treatment and diagnosis of **chlamydial** infection.
AUTHOR(S): **Probst, Peter** [Inventor, Reprint author];
Bhatia, Ajay [Inventor]; **Skeiky, Yasir A. W.** [Inventor]
CORPORATE SOURCE: Seattle, WA, USA
ASSIGNEE: Corixa Corporation
PATENT INFORMATION: US 6166177 20001226
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Dec. 26, 2000) Vol. 1241, No. 4. e-file.
CODEN: OGUPE7. ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 20 Jun 2001
Last Updated on STN: 19 Feb 2002

AB Compounds and methods for the diagnosis and treatment of **Chlamydial** infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a **Chlamydial** antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of **Chlamydial** infection in patients and in biological samples.

L13 ANSWER 28 OF 30 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation
on STN

ACCESSION NUMBER: 2001:39318 BIOSIS
DOCUMENT NUMBER: PREV200100039318
TITLE: Identification and characterization of a novel gene product encoding a CD8+ T cell epitope from the vacuolar intracellular pathogen, **Chlamydia trachomatis**.
AUTHOR(S): **Fling, S. P.** [Reprint author]; **Sutherland, R. A.** [Reprint author]; **Steele, L. N.**; **Hess, B.** [Reprint author]; **Maisonneuve, J.-F.** [Reprint author]; **Lampe, M. F.**; **Probst, P.** [Reprint author]; **Starnbach, M. N.**
CORPORATE SOURCE: Corixa Corporation, Seattle, WA, USA
SOURCE: FASEB Journal, (April 20, 2000) Vol. 14, No. 6, pp.

A1057. print.

Meeting Info.: Joint Annual Meeting of the American Association of Immunologists and the Clinical Immunology Society. Seattle, Washington, USA. May 12-16, 2000.

CODEN: FAJOEC. ISSN: 0892-6638.

DOCUMENT TYPE:

Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LANGUAGE:

English

ENTRY DATE:

Entered STN: 17 Jan 2001

Last Updated on STN: 12 Feb 2002

L13 ANSWER 29 OF 30 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation
on STN

ACCESSION NUMBER: 1994:546259 BIOSIS

DOCUMENT NUMBER: PREV199598005807

TITLE: Role of bacteria-specific T cells in the immunopathogenesis of reactive arthritis.

AUTHOR(S): Probst, Peter [Reprint author]; Hermann, Elisabeth; Fleischer, Bernhard [Reprint author]

CORPORATE SOURCE: Bernhard-Nocht Inst. Trop. Med., Bernhard-Nocht-Str. 74, D-20359, Germany

SOURCE: Trends in Microbiology, (1994) Vol. 2, No. 9, pp. 329-332.

ISSN: 0966-842X.

DOCUMENT TYPE:

Article

LANGUAGE:

English

ENTRY DATE:

Entered STN: 22 Dec 1994

Last Updated on STN: 22 Dec 1994

L13 ANSWER 30 OF 30 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation
on STN

ACCESSION NUMBER: 1991:219487 SCISEARCH

THE GENUINE ARTICLE: FF982

TITLE: MICROTUBULE-ASSOCIATED PROTEINS-DEPENDENT COLCHICINE STABILITY OF ACETYLATED COLD-LABILE BRAIN MICROTUBULES FROM THE ATLANTIC COD, GADUS-MORHUA

AUTHOR: BILLGER M (Reprint); STROMBERG E; WALLIN M

CORPORATE SOURCE: GOTHENBURG UNIV, DEPT ZOOPHYSIOL, COMPARAT NEUROSCI UNIT, S-40031 GOTHENBURG, SWEDEN (Reprint)

COUNTRY OF AUTHOR: SWEDEN

SOURCE: JOURNAL OF CELL BIOLOGY, (APR 1991) Vol. 113, No. 2, pp. 331-338.

ISSN: 0021-9525.

PUBLISHER: ROCKEFELLER UNIV PRESS, 222 E 70TH STREET, NEW YORK, NY 10021.

DOCUMENT TYPE: Article; Journal

FILE SEGMENT: LIFE

LANGUAGE: English

REFERENCE COUNT: 42

ENTRY DATE: Entered STN: 1994

Last Updated on STN: 1994

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Assembly of brain microtubule proteins isolated from the Atlantic cod, *Gadus morhua*, was found to be much less sensitive to colchicine than assembly of bovine brain microtubules, which was completely inhibited by low colchicine concentrations (10- μ M). The degree of disassembly by colchicine was also less for cod microtubules. The lack of colchicine effect was not caused by a lower affinity of colchicine to cod tubulin, as colchicine bound to cod tubulin with a

dissociation constant, $K(d)$, and a binding ratio close to that of bovine tubulin.

Cod brain tubulin was highly acetylated and mainly detyrosinated, as opposed to bovine tubulin. When cod tubulin, purified by means of phosphocellulose chromatography, was assembled by addition of DMSO in the absence of microtubule-associated proteins (MAPs), the microtubules became sensitive to low concentrations of colchicine. They were, however, slightly more stable to disassembly, indicating that posttranslational modifications induce a somewhat increased stability to colchicine. The stability was mainly MAPs dependent, as it increased markedly in the presence of MAPs. The stability was not caused by an extremely large amount of cod MAPs, since there were slightly less MAPs in cod than in bovine microtubules. When "hybrid" microtubules were assembled from cod tubulin and bovine MAPs, these microtubules became less sensitive to colchicine. This was not a general effect of MAPs, since bovine MAPs did not induce a colchicine stability of microtubules assembled from bovine tubulin. We can therefore conclude that MAPs can induce colchicine stability of colchicine labile acetylated tubulin.

FILE 'HOME' ENTERED AT 16:20:14 ON 21 JUL 2006

=> d his ful

(FILE 'HOME' ENTERED AT 16:15:10 ON 21 JUL 2006)
SET COST OFF

L1 FILE 'CAPLUS' ENTERED AT 16:15:35 ON 21 JUL 2006
1 SEA ABB=ON PLU=ON CT875 OR CT 875
D KWIC

FILE 'CAPLUS' ENTERED AT 16:16:26 ON 21 JUL 2006
D QUE
D .BEVERLY

L2 FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,
JICST-EPLUS, JAPIO' ENTERED AT 16:16:26 ON 21 JUL 2006
0 SEA ABB=ON PLU=ON L1

L3 FILE 'USPATFULL' ENTERED AT 16:16:46 ON 21 JUL 2006
14 SEA ABB=ON PLU=ON CT875 OR CT 875
L4 13 SEA ABB=ON PLU=ON L3 (L)CHLAMYD?
D 1-13 .BEVPAT

L5 FILE 'CAPLUS, MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,
JICST-EPLUS, JAPIO, USPATFULL' ENTERED AT 16:18:02 ON 21 JUL 2006
L6 2229 SEA ABB=ON PLU=ON "BHATIA A"?/AU
L7 1292 SEA ABB=ON PLU=ON "PROBST P"?/AU
L8 247 SEA ABB=ON PLU=ON "STROMBERG E"?/AU
L9 9 SEA ABB=ON PLU=ON L5 AND L6 AND L7
L10 45 SEA ABB=ON PLU=ON L5 AND (L6 OR L7)
L11 13 SEA ABB=ON PLU=ON L6 AND L7
L12 63 SEA ABB=ON PLU=ON (L9 OR L5 OR L6 OR L7) AND CHLAMYD?
L13 67 SEA ABB=ON PLU=ON L8 OR L10 OR L11
30 DUP REM L12 (37 DUPLICATES REMOVED)
D 1-30 IBIB ABS

FILE 'HOME' ENTERED AT 16:20:14 ON 21 JUL 2006

FILE HOME

FILE CAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Jul 2006 VOL 145 ISS 5
FILE LAST UPDATED: 20 Jul 2006 (20060720/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

10/762058

FILE MEDLINE

FILE LAST UPDATED: 20 Jul 2006 (20060720/UP). FILE COVERS 1950 TO DA

On December 11, 2005, the 2006 MeSH terms were loaded.

The MEDLINE reload for 2006 is now (26 Feb.) available. For details on the 2006 reload, enter HELP RLOAD at an arrow prompt (=>).

See also:

<http://www.nlm.nih.gov/mesh/>
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.ht
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html

OLDMEDLINE is covered back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 19 July 2006 (20060719/ED)

FILE EMBASE

FILE COVERS 1974 TO 21 Jul 2006 (20060721/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE WPIDS

FILE LAST UPDATED: 19 JUL 2006 <20060719/UP>

MOST RECENT DERWENT UPDATE: 200646 <200646/DW>

DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE, PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://scientific.thomson.com/support/patents/coverage/latestupdates/>

>>> PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE
http://www.stn-international.de/stndatabases/details/ipc_reform.html a
<http://scientific.thomson.com/media/scpdf/ipcrdwpi.pdf> <<<

>>> FOR FURTHER DETAILS ON THE FORTHCOMING DERWENT WORLD PATENTS INDEX ENHANCEMENTS PLEASE VISIT:
http://www.stn-international.de/stndatabases/details/dwpi_r.html <<<

10/762058

FILE CONFSCI
FILE COVERS 1973 TO 10 Jul 2006 (20060710/ED)

CSA has resumed updates, see NEWS FILE

FILE SCISEARCH

FILE COVERS 1974 TO 20 Jul 2006 (20060720/ED)

SCISEARCH has been reloaded, see HELP RLOAD for details.

FILE JICST-EPLUS
FILE COVERS 1985 TO 18 JUL 2006 (20060718/ED)

THE JICST-EPLUS FILE HAS BEEN RELOADED TO REFLECT THE 1999 CONTROLLED TERM (/CT) THESAURUS RELOAD.

FILE JAPIO
FILE LAST UPDATED: 3 APR 2006 <20060403/UP>
FILE COVERS APRIL 1973 TO DECEMBER 22, 2005

>>> GRAPHIC IMAGES AVAILABLE <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOT YET AVAILABLE IN THIS FILE.
USE IPC7 FORMAT FOR SEARCHING THE IPC. WATCH THIS SPACE FOR FURTHER
DEVELOPMENTS AND SEE OUR NEWS SECTION FOR FURTHER INFORMATION
ABOUT THE IPC REFORM <<<

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 20 Jul 2006 (20060720/PD)
FILE LAST UPDATED: 20 Jul 2006 (20060720/ED)
HIGHEST GRANTED PATENT NUMBER: US7080410
HIGHEST APPLICATION PUBLICATION NUMBER: US2006162035
CA INDEXING IS CURRENT THROUGH 20 Jul 2006 (20060720/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 20 Jul 2006 (20060720/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2006